Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Liposarcoma × lenvatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 114 Carcinoma, Renal Cell 30 Parkinson Disease 4, Autosomal Dominant Lewy Body 27 Neoplasms 24 Cholangiocarcinoma 21 Endometrial Neoplasms 16 Liver Neoplasms 14 Melanoma 13 Thyroid Neoplasms 11 Stomach Neoplasms 11 Biliary Tract Neoplasms 11 Carcinoma, Non-Small-Cell Lung 10 Ovarian Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 7 Recurrence 7 Neoplasm Metastasis 7 Breast Neoplasms 7 Uterine Cervical Neoplasms 6 Triple Negative Breast Neoplasms 5 Small Cell Lung Carcinoma 5 Colorectal Neoplasms 5 Pancreatic Neoplasms 4 Kidney Neoplasms 4 Esophageal Squamous Cell Carcinoma 4 Carcinoma, Transitional Cell 4 Adenocarcinoma 4 Thyroid Carcinoma, Anaplastic 3 Thyroid Cancer, Papillary 3 Solid Tumors 3 Neuroendocrine Tumors 3

Interventions

Doxorubicin 22 Radiotherapy 12 Ifosfamide 11 Trabectedin 10 pazopanib 5 Gemcitabine 5 ribociclib 4 pembrolizumab 4 Specimen Handling 4 Docetaxel 4 Biopsy 4 selinexor 3 palbociclib 3 eribulin 3 X-Rays 3 Imatinib Mesylate 3 Filgrastim 3 Cyclophosphamide 3 temsirolimus 2 romidepsin 2 pegfilgrastim 2 liposomal doxorubicin 2 cixutumumab 2 brostallicin 2 brigimadlin 2 belinostat 2 avelumab 2 abemaciclib 2 Vincristine 2 Temozolomide 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03526679 2025-12-05

LEADER

National Taiwan University Hospital

Phase 1/2 Completed

30 enrolled 9 charts

Leiomyosarcoma, Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡